Cantor Fitzgerald analyst Brandon Folkes raised his price target for Kindred Biosciences to $25 citing the positive top-line results from the company's pilot effectiveness study of KIND-016. The analyst now has increased conviction about Kindred's antibody pipeline, which includes KIND-016, a fully caninized, high-affinity IL-31 monoclonal antibody for the treatment of atopic dermatitis in dogs, an IL4/IL13 product that is likely to readout in early 2019, and a number of undisclosed antibody products. He reiterates an Overweight rating on the shares.